Gain Therapeutics (GANX)
- decide4yourself
- Apr 25, 2023
- 1 min read
Updated: Mar 10, 2024
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
******Disease-modifying mechanism of action demonstrated in extensive preclinical package For GT-02287 (No Other *Disease-Modifying* Therapeutics Currently Exist for the Treatment of Parkinsons)
***** See-TX Drug Discovery Platform alone is an extremely valuable asset
Accelerates drug discovery from 2+ years to less than 3 months
>100-fold increase in target hit rate
Applies across all therapeutic areas
Can target any protein in the human body, including the 90% of undruggable proteins
Full range of protein modulation as needed to affect disease cascade
Capital Structure
16,200,000 Shares Outstanding(02/09/24)
Current Market Cap at $5.04/Share (02/09/24) - $81,640,000
Cash Burn $4M/QTR $16M/Year
$25.7 M in cash and cash equivalents (9/30/22)
$0 Debt
Co-founder/Chairman
Management Team
Pipeline
See-TX Drug Discovery Platform
Lead Compound GT-02287
(Parkinson’s Disease / Gaucher Disease)
GT-02287 Market Opportunity
Investment Highlights
Comments